Pharmaceuticals – Global Group of Eight (G8) Industry Guide

reportlinker.com/p0191857/Pharmaceuticals—Global-Group-of-Eight-G8-Industry-Guide.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pharmaceutical

* Provides textual analysis of the industry’s prospects, competitive landscape and profiles of the leading companies

* Incorporates in-depth five forces competitive environment analysis and scorecards

* Includes a five-year forecast of the industry

Among the G8 countries, the US holds the major share of the pharmaceuticals industry. It accounted for a share of 49.1% in 2011.

* Spot future trends and developments

* Inform your business decisions

* Add weight to presentations and marketing materials

* Save time carrying out entry-level research

Market values have been calculated at ex-factory prices (the value at which manufacturers sell the drugs to distributors).

Any currency conversions used in the production of this report have been calculated at constant 2011 annual average exchange rates.

Table 1: G8 pharmaceuticals industry, revenue($bn), 2007-16 16

Table 2: G8 Pharmaceuticals industry, revenue by country (%), 2011 17

Table 3: G8 pharmaceuticals industry, revenue by country ($bn), 2007-11 18

Table 4: G8 pharmaceuticals industry forecast, revenue by country ($bn), 2011-16 19

Table 85: Johnson & Johnson: key facts 140

Table 86: Johnson & Johnson: key financials ($) 141

Table 87: Johnson & Johnson: key financial ratios 141

Table 88: Pfizer Inc.: key facts 143

Table 89: Pfizer Inc.: key financials ($) 144

Table 90: Pfizer Inc.: key financial ratios 144

Table 91: AstraZeneca PLC: key facts 146

Table 92: AstraZeneca PLC: key financials ($) 147

Table 93: AstraZeneca PLC: key financial ratios 148

Table 94: GlaxoSmithKline Plc: key facts 150

Table 95: GlaxoSmithKline Plc: key financials ($) 151

Table 96: GlaxoSmithKline Plc: key financials () 152

Table 97: GlaxoSmithKline Plc: key financial ratios 152

Table 98: Novartis AG: key facts 154

Table 99: Novartis AG: key financials ($) 155

Table 100: Novartis AG: key financial ratios 155

Table 101: Chiesi Farmaceutici S.P.A.: key facts 157

Table 102: Menarini Group, The: key facts 159

Table 103: Takeda Pharmaceutical Company Limited: key facts 160

Table 104: Takeda Pharmaceutical Company Limited: key financials ($) 161

Table 105: Takeda Pharmaceutical Company Limited: key financials () 161

Table 106: Takeda Pharmaceutical Company Limited: key financial ratios 161

Table 107: Daiichi Sankyo Co., Ltd.: key facts 163

Table 108: Daiichi Sankyo Co., Ltd.: key financials ($) 164

Table 109: Daiichi Sankyo Co., Ltd.: key financials () 164

Table 110: Daiichi Sankyo Co., Ltd.: key financial ratios 164

Table 111: Mitsubishi Tanabe Pharma Corporation: key facts 166

Table 112: Mitsubishi Tanabe Pharma Corporation: key financials ($) 167

Table 113: Mitsubishi Tanabe Pharma Corporation: key financials () 167

Table 114: Mitsubishi Tanabe Pharma Corporation: key financial ratios 167

Table 115: Pharmstandard OJSC: key facts 169

Table 116: Pharmstandard OJSC: key financials ($) 169

Table 117: Pharmstandard OJSC: key financials (RUB) 170

Table 118: Pharmstandard OJSC: key financial ratios 170

Table 119: Sanofi: key facts 172

Table 120: Sanofi: key financials ($) 173

Table 121: Sanofi: key financials (€) 173

Table 122: Sanofi: key financial ratios 173

Table 123: Bayer AG: key facts 175

Table 124: Bayer AG: key financials ($) 176

Table 125: Bayer AG: key financials (€) 176

Table 126: Bayer AG: key financial ratios 177

Table 127: Merck & Co., Inc.: key facts 179

Table 128: Merck & Co., Inc.: key financials ($) 180

Table 129: Merck & Co., Inc.: key financial ratios 180

Nicolas Bombourg

Reportlinker

US: (805)652-2626

Intl: +1 805-652-2626

SOURCE Reportlinker